Men diagnosed as having prostate cancer need to be treated quickly and aggressively with surgery or radiotherapy rather than put under active surveillance if they have inherited the BRCA2 mutation, a study has found. The study, published in the Journal of Clinical Oncology on 8 April,1 found ...
[10] Sumanasuriya S & De Bono J. Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise. Cold Spring Harb Perspect Med. 2018;8(6):a030635. [11] Scott RJ, et al. Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant p...
BACKGROUND: Elevated expression of interleukin-6 (IL-6) is implicated in the progression of hormone refractory prostate cancer. Previous studies demonstrated that IL-6 promotes androgen-independent growth of prostate cancer cells. In this study, the effect of IL-6 on apoptosis induced by androgen ...
Defects in homologous recombination repair genes, such as BRCA1/2, are also being increasingly detected in individuals with advanced prostate cancer. We present the case of a 65-yr-old man with a germline BRCA2 mutation who developed explosive treatment-emergent, small-cell neuroendocrine prostate ...
In BRCA2-overexpressing PC-3 cells, transient transfection with a constitutively active PI3-kinase mutant or treatment with the MAPK/ERK inhibitor PD98059 rescued MMP-9 levels and restored the migratory and invasive capabilities. Consistently, PI3-kinase inhibition with a dominant-negative mutant or ...
22、f brca1 and brca2 mutation carriersj.oncologist,2016,21(7):869-874.12 gallagher d j,cronin a m,milowsky m i,et al.germline brca mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancerj.bju international,2012,109(5):713-719.13...
[2]Olmos D, Lorente D, Alameda D, et al. Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status. J Clin Oncol. 2023;41(supp...
Current treatment modalities for incident cases do not differ for age- and stage-matched sporadic breast cancer cases; although clinical trials with PARP inhibitors are currently underway. ▪ The prognosis for BRCA2-associated breast cancers has not been clearly established Read more View chapterExplo...
BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that es
Identifying more male carriers ofBRCA1/2PVs will maximize opportunities for cancer early detection, targeted risk management, and cancer treatment for males, along with facilitating opportunities for risk reduction and prevention in their family members, thereby decreasing the burden of hereditary cancer....